XTX Topco Ltd Trims Stock Position in Pyxis Oncology, Inc. (NASDAQ:PYXS)

XTX Topco Ltd decreased its holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS) by 44.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,290 shares of the company’s stock after selling 29,572 shares during the quarter. XTX Topco Ltd owned approximately 0.06% of Pyxis Oncology worth $120,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of PYXS. Vestal Point Capital LP purchased a new stake in Pyxis Oncology in the fourth quarter valued at approximately $792,000. Cable Car Capital LLC purchased a new stake in shares of Pyxis Oncology during the 4th quarter valued at $111,000. SG Americas Securities LLC acquired a new stake in shares of Pyxis Oncology during the 1st quarter worth $59,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Pyxis Oncology in the 1st quarter worth $351,000. Finally, Vanguard Group Inc. boosted its holdings in Pyxis Oncology by 7.3% in the first quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock valued at $5,970,000 after acquiring an additional 94,740 shares during the last quarter. Institutional investors and hedge funds own 39.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PYXS. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Friday, August 16th. Royal Bank of Canada reissued an “outperform” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research note on Thursday, September 19th. Finally, Stifel Nicolaus assumed coverage on Pyxis Oncology in a research report on Thursday, August 8th. They issued a “buy” rating and a $10.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Pyxis Oncology currently has a consensus rating of “Buy” and an average target price of $9.00.

Pyxis Oncology Stock Down 4.4 %

PYXS stock opened at $3.51 on Wednesday. The company has a market capitalization of $206.70 million, a PE ratio of -2.58 and a beta of 1.28. The stock’s 50 day moving average is $3.60 and its two-hundred day moving average is $3.88. Pyxis Oncology, Inc. has a 52-week low of $1.35 and a 52-week high of $6.85.

Pyxis Oncology (NASDAQ:PYXS) last issued its earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. As a group, sell-side analysts anticipate that Pyxis Oncology, Inc. will post -1.07 EPS for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.